The Supreme Court is poised to hear significant cases concerning patent law and the accessibility of generic medications, including a contentious dispute over fish oil pills. This legal battle may lead to rising prescription drug costs and has implications for the generics market, particularly regarding skinny labeling—a process that allows manufacturers to market generic drugs with limited indications. Legal experts and pharmaceutical marketers are closely monitoring these developments, which also encompass broader issues surrounding the relationship between original manufacturers and their generic counterparts.